Cargando…

Corrigendum to “Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma”

Detalles Bibliográficos
Autores principales:	Fatima, Naz, Akhtar, Tasleem, Sheikh, Nadeem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523188/ https://www.ncbi.nlm.nih.gov/pubmed/28770186 http://dx.doi.org/10.1155/2017/1548919

Ejemplares similares

Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma
por: Fatima, Naz, et al.
Publicado: (2017)

Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis [Corrigendum]
Publicado: (2022)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum]
Publicado: (2020)

Corrigendum to “The Oncogenic Role of ARG1 in Progression and Metastasis of Hepatocellular Carcinoma”
por: You, Jia, et al.
Publicado: (2019)

Corrigendum to: Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

Corrigendum to “Cell Cycle Genes Are Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma”
por: Liping, Xu, et al.
Publicado: (2020)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2023)

The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population [Corrigendum]
Publicado: (2021)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Corrigendum to “Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells”
por: Huang, Suning, et al.
Publicado: (2020)

miR-500a-3p is a Potential Prognostic Biomarker in Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection [Corrigendum]
Publicado: (2021)

Downregulation of CENPK Suppresses Hepatocellular Carcinoma Malignant Progression through Regulating YAP1 [Corrigendum]
Publicado: (2022)

Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum]
Publicado: (2021)

Corrigendum to “System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”
por: Xu, Jun Hui, et al.
Publicado: (2022)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

[Corrigendum] MicroRNA‑92a contributes to tumor growth of human hepatocellular carcinoma by targeting FBXW7
por: Yang, Wei, et al.
Publicado: (2023)

Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum]
Publicado: (2020)

Corrigendum to Long Noncoding RNA PTTG3P Expression Is an Unfavorable Prognostic Marker for Patients With Hepatocellular Carcinoma
Publicado: (2020)

Corrigendum to “EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src”
por: Zhao, Ran, et al.
Publicado: (2021)

Corrigendum to Hypoxia‐induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway
Publicado: (2022)

Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo [Corrigendum]
Publicado: (2020)

GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”
por: Qian, Lei, et al.
Publicado: (2022)

Corrigendum to “Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway”
por: Gao, Qingzhu, et al.
Publicado: (2023)

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
Publicado: (2020)

Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis [Corrigendum]
Publicado: (2019)

Corrigendum: Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma
por: Shehta, Ahmed, et al.
Publicado: (2021)

Corrigendum to “TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma” [EBioMedicine 40 (2019) 446–456]
por: Tan, Wenliang, et al.
Publicado: (2022)

Delivery Of miR-375 And Doxorubicin By Lipid-Coated Hollow Mesoporous Silica Nanoparticles To Overcome Multiple Drug Resistance In Hepatocellular Carcinoma [Corrigendum]
Publicado: (2019)

Corrigendum to ‘Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and integrative review’ [Trends in Food Science & Technology 120 (2022) 174–192]
por: Xavier-Santos, Douglas, et al.
Publicado: (2022)

Corrigendum to: Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
Publicado: (2022)

Corrigendum: Prevalence of Depression and Glucose Abnormality in an Urbanizing Rural Population of Bangladesh
por: Natasha, Khurshid, et al.
Publicado: (2016)

Corrigendum to “Extraction of HCV-RNA from Plasma Samples: Development towards Semiautomation”
por: Amin, Imran, et al.
Publicado: (2016)

Corrigendum to “Effect of Intervention in Subjects with High Risk of Diabetes Mellitus in Pakistan”
por: Hydrie, Muhammad Zafar Iqbal, et al.
Publicado: (2015)

Corrigendum to “The Chinese Medicine, Jiedu Recipe, Inhibits the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma via the Regulation of Smad2/3 Dependent and Independent Pathways”
por: Liang, Shufang, et al.
Publicado: (2022)

miR-221 Suppression Through Nanoparticle-Based miRNA Delivery System for Hepatocellular Carcinoma Therapy and Its Diagnosis as a Potential Biomarker [Corrigendum]
Publicado: (2020)

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
por: D'Angelo, S. P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1fuj69c18r07japcu2gf2q1bhu